IGF-1 and Its Binding Proteins Are Linked to Fatty Liver Severity and Blood Sugar Control
Lower liver IGF-1 expression and specific shifts in IGF-binding proteins are associated with worse fatty liver disease, more fibrosis, and poorer blood sugar control — and growth hormone-releasing hormone treatment can modify these binding proteins.
Quick Facts
What This Study Found
Hepatic IGF-1 mRNA was significantly lower in individuals with more severe steatosis (fat accumulation) and higher NAFLD Activity Scores, and was inversely related to blood glucose parameters independent of circulating IGF-1 levels. This means the liver's own IGF-1 production — not just what's in the blood — matters for metabolic health.
Among the binding proteins, IGFBP2 and IGFBP4 were lower while IGFBP6 and IGFBP7 were higher with increasing steatosis. Notably, IGFBP7 increased with fibrosis severity, making it a potential marker for scarring. GHRH treatment increased circulating IGFBP-1 and IGFBP-3 while decreasing IGFBP-2 and IGFBP-6, demonstrating that the GH axis can modify these binding protein profiles.
Key Numbers
61 patients; 39 with liver RNA-Seq; IGF1 inversely associated with steatosis/NAS; IGFBP2/4 low in severe disease; IGFBP6/7 high; IGFBP7 increased with fibrosis; GHRH increased IGFBP-1/3, decreased IGFBP-2/6
How They Did This
This was a secondary analysis of data from a randomized clinical trial of GHRH conducted at two US academic medical centers. The 61 participants were HIV-infected adults aged 18-70 with at least 5% liver fat. Of these, 39 had RNA-Seq data from liver biopsies, allowing researchers to measure actual gene expression of IGF-1 and binding proteins in liver tissue and correlate these with histopathology (steatosis, inflammation, fibrosis) and glucose metabolism measures.
Why This Research Matters
NAFLD affects roughly a quarter of the global population and is a leading cause of liver disease, yet treatment options remain limited. This study reveals that the IGF system in the liver is not just a passive bystander but actively linked to disease progression. The finding that GHRH can modify binding protein profiles opens a potential therapeutic avenue — and the divergent roles of different IGFBPs suggest that targeted approaches, not blanket IGF manipulation, will be needed.
The Bigger Picture
This study connects growth hormone biology to liver disease in a way that goes beyond simple IGF-1 blood levels. By looking at what the liver itself is producing, it reveals a more nuanced picture of how the GH-IGF axis intersects with metabolic liver disease. It also positions GHRH analogs — peptides already used in other contexts — as potential tools for modifying the IGF binding protein landscape in NAFLD patients.
What This Study Doesn't Tell Us
The associations are cross-sectional and cannot prove causation. The study population was HIV-infected, which may limit generalizability to the broader NAFLD population since HIV and antiretroviral therapy can independently affect metabolism. The liver biopsy subset was small (39 patients), and multiple statistical comparisons increase the risk of false positive findings. GHRH effects on circulating IGFBPs may not reflect hepatic changes.
Questions This Raises
- ?Would GHRH treatment actually improve liver histology in NAFLD patients, or does it just change binding protein levels without clinical benefit?
- ?Do these IGF-1 and IGFBP relationships hold true in non-HIV NAFLD populations?
- ?Could IGFBP7 serve as a non-invasive blood biomarker for liver fibrosis severity?
Trust & Context
- Key Stat:
- n=61 with NAFLD In this clinical trial population, lower hepatic IGF-1 expression was independently associated with worse steatosis, higher disease activity scores, and poorer glucose control — suggesting the liver's own IGF-1 production is a key metabolic signal.
- Evidence Grade:
- This is a secondary analysis of a randomized clinical trial with liver biopsy data and RNA-Seq. While it provides moderate-quality human evidence with direct tissue measurements, the correlational design and relatively small sample limit causal conclusions.
- Study Age:
- Published in 2021, this study reflects current understanding of the GH-IGF axis in NAFLD. The field has continued to evolve with growing interest in GHRH analogs and metabolic liver disease, keeping these findings relevant.
- Original Title:
- Relationship of IGF-1 and IGF-Binding Proteins to Disease Severity and Glycemia in Nonalcoholic Fatty Liver Disease.
- Published In:
- The Journal of clinical endocrinology and metabolism, 106(2), e520-e533 (2021)
- Authors:
- Stanley, Takara L(3), Fourman, Lindsay T, Zheng, Isabel, McClure, Colin M, Feldpausch, Meghan N, Torriani, Martin, Corey, Kathleen E, Chung, Raymond T, Lee, Hang, Kleiner, David E, Hadigan, Colleen M, Grinspoon, Steven K
- Database ID:
- RPEP-05789
Evidence Hierarchy
Participants are randomly assigned to treatment or placebo groups to test cause and effect.
What do these levels mean? →Frequently Asked Questions
What is IGF-1 and why does it matter for the liver?
IGF-1 (insulin-like growth factor 1) is a peptide hormone primarily produced by the liver in response to growth hormone. Beyond its role in growth, it helps regulate glucose and fat metabolism in the liver. When IGF-1 production drops, it appears to be associated with more fat accumulation and worse metabolic function in the liver.
Could growth hormone treatments help people with fatty liver disease?
This study found that GHRH (growth hormone-releasing hormone) treatment changed the levels of several IGF-binding proteins in ways that could theoretically be beneficial. However, whether this actually improves liver health or just changes blood markers needs to be tested in dedicated clinical trials — we can't draw treatment conclusions from this data alone.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05789APA
Stanley, Takara L; Fourman, Lindsay T; Zheng, Isabel; McClure, Colin M; Feldpausch, Meghan N; Torriani, Martin; Corey, Kathleen E; Chung, Raymond T; Lee, Hang; Kleiner, David E; Hadigan, Colleen M; Grinspoon, Steven K. (2021). Relationship of IGF-1 and IGF-Binding Proteins to Disease Severity and Glycemia in Nonalcoholic Fatty Liver Disease.. The Journal of clinical endocrinology and metabolism, 106(2), e520-e533. https://doi.org/10.1210/clinem/dgaa792
MLA
Stanley, Takara L, et al. "Relationship of IGF-1 and IGF-Binding Proteins to Disease Severity and Glycemia in Nonalcoholic Fatty Liver Disease.." The Journal of clinical endocrinology and metabolism, 2021. https://doi.org/10.1210/clinem/dgaa792
RethinkPeptides
RethinkPeptides Research Database. "Relationship of IGF-1 and IGF-Binding Proteins to Disease Se..." RPEP-05789. Retrieved from https://rethinkpeptides.com/research/stanley-2021-relationship-of-igf1-and
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.